Literature DB >> 22644031

In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Teresa Spanu1, Giulia De Angelis, Michela Cipriani, Barbara Pedruzzi, Tiziana D'Inzeo, Maria Adriana Cataldo, Gabriele Sganga, Evelina Tacconelli.   

Abstract

Although resistance to tigecycline has been reported in surveillance studies, very few reports have described the emergence of resistance in vivo. We report two cases of patients with infections due to SHV-12-producing Klebsiella pneumoniae and K. pneumoniae carbapenemase-3 (KPC-3)-producing Escherichia coli, which developed tigecycline resistance in vivo after treatment. The reported limited experience underlines the risk of occurrence of a tigecycline MIC increase under treatment pressure.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22644031      PMCID： PMC3421558          DOI： 10.1128/AAC.00234-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

1.  What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.

Authors:  David M Livermore; Marina Warner; Shazad Mushtaq; Michel Doumith; Jiancheng Zhang; Neil Woodford
Journal:  Int J Antimicrob Agents       Date:  2011-03-22       Impact factor: 5.283

2.  Application of minimal sequence quality values prevents misidentification of the blaSHV type in single bacterial isolates carrying different SHV extended-spectrum beta-lactamase genes.

Authors:  Nashwan Al Naiemi; Kim Schipper; Birgitta Duim; Aldert Bart
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

3.  Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient.

Authors:  C Rodríguez-Avial; I Rodríguez-Avial; P Merino; J J Picazo
Journal:  Clin Microbiol Infect       Date:  2011-07-01       Impact factor: 8.067

4.  Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae.

Authors:  Alexey Ruzin; Melissa A Visalli; David Keeney; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 5.  Tigecycline: a glycylcycline antimicrobial agent.

Authors:  Thien-Ly Doan; Horatio B Fung; Dhara Mehta; Paul F Riska
Journal:  Clin Ther       Date:  2006-08       Impact factor: 3.393

6.  Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.

Authors:  Anton Y Peleg; Brian A Potoski; Rhonda Rea; Jennifer Adams; Jigme Sethi; Blair Capitano; Shahid Husain; Eun J Kwak; Sunil V Bhat; David L Paterson
Journal:  J Antimicrob Chemother       Date:  2006-11-01       Impact factor: 5.790

7.  Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

Authors:  Charles R Dean; Melissa A Visalli; Steven J Projan; Phaik-Eng Sum; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.

Authors:  Jason J Schafer; Debra A Goff; Kurt B Stevenson; Julie E Mangino
Journal:  Pharmacotherapy       Date:  2007-07       Impact factor: 4.705

9.  RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae.

Authors:  David Keeney; Alexey Ruzin; Patricia A Bradford
Journal:  Microb Drug Resist       Date:  2007       Impact factor: 3.431

10.  A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].

Authors:  María E Oliva; Arcot Rekha; Albert Yellin; Jacyr Pasternak; Maria Campos; Gilbert M Rose; Timothy Babinchak; Evelyn J Ellis-Grosse; Evan Loh
Journal:  BMC Infect Dis       Date:  2005-10-19       Impact factor: 3.090
View more
  23 in total

1.  Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae.

Authors:  Masayuki Nigo; Catalina Salinas Cevallos; Krystina Woods; Vicente Maco Flores; Gweneth Francis; David C Perlman; Manuel Revuelta; Donna Mildvan; Mary Waldron; Tessa Gomez; Sanjana Koshy; Tomasz Jodlowski; William Riley; Jörg J Ruhe
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

2.  Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases, GES-22 and VIM-35.

Authors:  Mariana Castanheira; Sarah E Costello; Leah N Woosley; Lalitagauri M Deshpande; Todd A Davies; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

3.  Decreased Susceptibility to Tigecycline Mediated by a Mutation in mlaA in Escherichia coli Strains.

Authors:  Fang He; Juan Xu; Jianfeng Wang; Qiong Chen; Xiaoting Hua; Ying Fu; Yunsong Yu
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

4.  Antibiofilm peptides increase the susceptibility of carbapenemase-producing Klebsiella pneumoniae clinical isolates to β-lactam antibiotics.

Authors:  Suzana Meira Ribeiro; César de la Fuente-Núñez; Beverlie Baquir; Célio Faria-Junior; Octávio L Franco; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

Review 5.  Tetracycline Antibiotics and Resistance.

Authors:  Trudy H Grossman
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

6.  Synergistic activity of synthetic N-terminal peptide of human lactoferrin in combination with various antibiotics against carbapenem-resistant Klebsiella pneumoniae strains.

Authors:  P Morici; W Florio; C Rizzato; E Ghelardi; A Tavanti; G M Rossolini; A Lupetti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-03       Impact factor: 3.267

7.  IS5 element integration, a novel mechanism for rapid in vivo emergence of tigecycline nonsusceptibility in Klebsiella pneumoniae.

Authors:  Lindsey E Nielsen; Erik C Snesrud; Fatma Onmus-Leone; Yoon I Kwak; Ricardo Avilés; Eric D Steele; Deena E Sutter; Paige E Waterman; Emil P Lesho
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

8.  Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method.

Authors:  Dror Marchaim; Jason M Pogue; Oran Tzuman; Kayoko Hayakawa; Paul R Lephart; Hossein Salimnia; Theresa Painter; Marcus J Zervos; Laura E Johnson; Mary Beth Perri; Pamela Hartman; Rama V Thyagarajan; Sharon Major; Melanie Goodell; Mohamad G Fakih; Laraine L Washer; Duane W Newton; Anurag N Malani; Jason M Wholehan; Lona Mody; Keith S Kaye
Journal:  J Clin Microbiol       Date:  2014-03-05       Impact factor: 5.948

9.  Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance.

Authors:  Laura Villa; Claudia Feudi; Daniela Fortini; Aurora García-Fernández; Alessandra Carattoli
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

10.  Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.

Authors:  Mariana Castanheira; Sarah E Farrell; Kevin M Krause; Ronald N Jones; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.